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Background: Psychosocial factors including depression, anxiety and lower social support are common in patients
with chronic kidney disease (CKD). However the influence of these potentially modifiable risk factors on morbidity
and mortality in this renal population is unknown. The Tasmanian Chronic Kidney Disease study is a prospective
cohort study which aims to examine the influence of both biomedical and psychosocial factors on disease
progression, decision making and length and quality of life in adults with severe CKD, prior to kidney replacement
therapy (KRT). This paper describes the recruitment, baseline characteristics and initial follow-up of pilot participants.
Methods: Adults aged > 18 years with stage 4 CKD (eGFR 15–29 mls/min/1.73 m2) and not receiving dialysis were
recruited via treating physicians. Measures included depression (9-item Patient Health Questionnaire), anxiety (Beck
Anxiety Inventory) and social support (Multidimensional Scale of Perceived Social Support). Primary outcomes were
kidney disease progression, use of KRT and health-related quality of life (Kidney Disease and Quality of Life Short
Form and the EQ-5D).
Results: Of those invited (n = 105), 49 provided consent and completed baseline assessment. There were no
significant differences between responders and non-responders in age, gender and socio-economic status (all
p > 0.05). Participants were predominantly male (63.3%) with a mean age of 72.6 ± 10.2 years. Mean serum
creatinine was 241 ± 62 μmol/L with mean eGFR 22 ± 5 mls/min/1.73 m2. Prevalence of major depression and
moderate to severe anxiety was 10% and 9% respectively. Less severe depression and fewer anxiety symptoms
were associated with higher health-related quality of life. Follow-up at 10-months showed CKD progression in 34%
of participants (use of KRT in 16%, stage 5 CKD without KRT in 18%), one death, with the remainder stable at CKD
stage 3 or 4.
Conclusions: Results indicate that a larger prospective study is feasible and has the capacity to examine the
influence of biomedical and psychosocial factors on kidney disease progression, use of dialysis and transplantation,
and salient personal and economic outcomes. Findings have the potential to provide an evidence base for revising
healthcare provision in order to optimize the care of patients with CKD.
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Chronic kidney disease (CKD) is a progressive disease
associated with decreased quality of life, progression to
end-stage kidney disease (ESKD), and increased risk of
cardiovascular disease and mortality. Evidence from vari-
ous chronic disease settings indicates that psychosocial
factors including depression, anxiety and social isolation
have a significant impact on quality of life, biological fac-
tors and disease progression [1-3]. Targeted psychosocial
interventions have been shown to improve quality of life,
treatment compliance, physical functioning and reduce
the risk of cardiovascular disease [1,4]. However, despite
the increasing social and economic burden of CKD [5],
our understanding of the influence of psychosocial fac-
tors on patients in this population is limited. Examining
the influence of potentially modifiable psychosocial fac-
tors on the progression of disease and management of
those with advanced CKD has the capacity to identify
areas for psychosocial intervention in this vulnerable
and growing population.
Research examining psychosocial factors in renal pop-
ulations is relatively new and has focussed predomin-
antly on patients with ESKD. Depression is associated
with increased mortality and decreased quality of life in
patients on dialysis [6-8], however few studies have ex-
amined the influence of depression on disease progres-
sion and adverse outcomes in patients with CKD prior
to the initiation of kidney replacement therapy (KRT)
(dialysis or transplantation) [9,10]. These studies indicate
that clinical depression [9] and elevated depressive
symptoms [10] are independent predictors of clinical
outcomes, including initiation of dialysis, hospitalization
or death in CKD patients. In contrast, Kop and col-
leagues found that higher depressive symptoms were
associated with subsequent acute kidney injury but not
renal function decline, hospitalization or initiation of
dialysis [11].
In comparison to depression, there is a paucity of re-
search examining the influence of anxiety and social iso-
lation in patients with kidney disease. Anxiety disorders
are often perceived to represent symptoms of depression
rather than independent conditions and therefore have
been relatively understudied in this medical population.
There is a high prevalence of anxiety in patients treated
with hemodialysis [12] however the impact of anxiety in
CKD patients not on dialysis is unknown. Finally, while
lower perceived social support is associated with de-
creased quality of life [13,14] and increased mortality in
ESKD [13-15] this relationship has not been investigated
in CKD prior to KRT.
The aim of the current pilot study is to examine the
feasibility and efficacy of the Tasmanian Chronic Kidney
Disease study, a prospective cohort study of non-dialyzed
adults with severe CKD living in Tasmania, Australia [16]with a minimum follow-up of 3-years. The main objec-
tives of this study are to examine the relative influence of
both biomedical and psychosocial factors on kidney dis-
ease progression, use of KRT and overall length and qual-
ity of life. Findings will have direct translation into clinical
practice (by identifying psychosocial factors as important
predictors of outcomes), healthcare service provision (by
focusing health services on quality of life rather than
extending life at all costs) and healthcare policy. The
current paper describes the study design, the key clinical
and psychosocial characteristics of pilot participants at
baseline, and clinical progression at 10-month follow-up.
Methods
Inclusion criteria and recruitment
All adults living in Tasmania aged > 18 years with an esti-
mated glomerular filtration rate (eGFR) 15–29 mls/min/
1.73 m2 on a single reading in the previous 3-months and
not receiving dialysis between 1 July 2010 and 9 August
2011 were eligible for inclusion in the pilot study. Poten-
tial participants were identified by use of the Clinical
Audit Tool [17] or through a direct request to pathology
services to identify any patient with an eGFR 15–29 mls/
min/1.73 m2 for the first time during the recruitment
period. Recruitment from primary care was irrespective of
(and separate to) referral to a renal physician. Eligible par-
ticipants were sent an enrolment package in the mail by
their treating doctor. This consisted of an information
booklet and a letter requesting return of a signed consent
form indicating participation. If consent forms were not
returned within two weeks potential participants were
followed-up by phone. The pilot study was approved by
the Tasmanian Health and Medical Human Research Eth-
ics Committee (protocol H0011543).
Procedure
Participants were sent self-report questionnaires prior to
attending a study clinic where baseline clinical and la-
boratory data including height, weight, blood pressure
and hemoglobin were measured and functional capacity
was assessed. Participants unable to attend a clinic had
measurements taken at their place of residence. Clinic
assessments took approximately 1.5 hours.
Measures
Psychosocial and sociodemographic factors
Psychosocial factors were self-reported using the Patient
Health Questionnaire [18], the Beck Anxiety Inventory
[19] and the Multidimensional Scale of Perceived Social
Support [20]. All measures have previously been vali-
dated in people with kidney disease and were used to
facilitate comparisons within the literature. The Beck
Anxiety Inventory was included in order to distinguish
symptoms of anxiety from those of depression.
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a 9-item screening and diagnostic tool devised to assess
the presence and severity of depression. Respondents rate
how often they have experienced depressive thoughts or
feelings over the prior 2-weeks on a scale ranging from 0
(not at all) to 3 (nearly every day) with total scores ranging
from 0 to 27. Scores ≥ 10 have sensitivity and specificity of
92% for a diagnosis of major depression in patients on
hemodialysis [21].
Beck Anxiety Inventory (BAI) The BAI is a 21-item
screening tool designed specifically to distinguish symp-
toms of anxiety from those of depression. It also includes
an item examining fear of death (thanatophobia) which
may influence decision making concerning treatment. Re-
spondents rate the extent to which each symptom has
bothered them in the past month, ranging from 0 (not at
all) to 3 (severely, I could barely stand it). Total scores
range from 0 to 63 with scores of ≥ 16 indicating moderate
to severe levels of anxiety [22]. The BAI has demonstrated
high internal consistency and adequate discriminant valid-
ity in older patients in primary care [23].
Multidimensional Scale of Perceived Social Support
(MSPSS) The MSPSS is a 12-item inventory which as-
sesses overall perceived social support. The scale contains
three subscales, family, friends, and significant others,
which are averaged to comprise an overall score. Scores
are reported on seven-point scale, with higher scores indi-
cating higher perceived social support. Lower levels of
perceived social support derived using this scale have pre-
dicted poorer survival in hemodialysis patients [24].
Sociodemographic and health information including
marital status, education level, employment status, house-
hold income and smoking history was collected via ques-
tionnaire. Area-level socio-economic status (SES) based
on residential postcode was derived using the Australian
Bureau of Statistics socioeconomic index for areas (SEIFA)
[25]. The SEIFA is a summary of four indices designed to
measure different aspects of SES based on questions asked
in the 2001 Census of Population and Housing [25]. The
Index of Disadvantage is derived from attributes including
low income, low educational attainment, high unemploy-
ment and employment in unskilled occupations. For the
current analysis postcodes were divided into four quartiles
according to ranking in this index, the first quartile
representing greater disadvantage compared with other
geographical areas.
Biomedical factors
Information regarding the number and severity of med-
ical comorbidities was obtained from the participant’s
treating doctor using a modified Charlson comorbidity
index (CMI) [26]. Body mass index (BMI) (kg/m2) wasderived from objectively measured height and weight
and categorized according to standard BMI cut-points
[27]. Cognitive function was assessed objectively using
the Modified Mini-Mental State Examination [28] and
via self-report using the cognitive function subscale of
the Kidney Disease Quality of Life short-form (KDQOL-
SF 1.3) [29]. Functional status was reported by the
participant’s treating doctor using the Karnofsky Per-
formance Scale [30] while functional ability was self-
reported using the Activities of Daily Living index [31]
and the Instrumental Activities of Daily Living scale
[32]. Functional capacity was assessed using hand grip
dynometry (average of two measurements) and gait
speed (time taken to walk 5-metres) using standardized
protocols. Healthcare decision making was self-reported
using the Autonomy Preference Index [33] and the
Krantz Health Opinion Survey [34].
Modified Mini-Mental State Examination (3MS) The
3MS is an interviewer administered test of global cogni-
tive function which assesses orientation, attention, lan-
guage, and memory. Scores range from 0 to 100 with
higher scores indicating better cognitive function. The
3MS is more sensitive to early cognitive changes than
the mini-mental state with scores < 80 having a sensitiv-
ity of 97% and a specificity of 91% for detecting demen-
tia [28].
Kidney Disease Quality of Life short-form (KDQOL-
SF 1.3) The KDQOL-SF combines the 36 generic items
of the SF-36 with 43 kidney disease-targeted items. Eleven
subscales are defined from the kidney disease-targeted
items, resulting in a total of 19 subscales (i.e., eight generic
and 11 targeted to patients with kidney disease and treated
by dialysis). Responses are weighted and transformed to
scores ranging from 0 to 100, with higher scores indicat-
ing better self-assessed health-related quality of life. The
SF-36 has two subscales, the physical component sum-
mary (SF-36 PCS) and the mental component summary
(SF-36 MCS). The KDQOL-SF 1.3 cognitive function
subscale has been validated in people with CKD with a
median score of 87 [35].
Karnofsky Performance Scale (KPS) The KPS is a
physician-rated measure of a patient’s functional status.
Scores range from 0 to 100 with a score of 100 indicat-
ing full capacity to carry out normal activities. Scores <
70 indicate that some level of assistance is needed to
carry out daily activities. Lower KPS scores have predicted
higher risk of mortality in patients with ESKD [36].
Activities of Daily Living (ADL) The ADL assesses
functional status as a measure of the patient’s ability to
perform activities of daily living independently. Scores
50 agreed to participate and provided 
informed consent
112 eligible patients identified
49 provided baseline data
19 refused to participate
1 withdrew consent
14 lost to follow-up
7 could not be contacted
105 invited to participate
22 did not respond
Figure 1 Description of the Tasmanian Chronic Kidney Disease
study pilot cohort.
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tion. The scale is sensitive to changes in declining health
status and has been used effectively among older adults
in a variety of care settings.
Instrumental Activities of Daily Living (IADL) The
IADL assesses independent living skills in order to iden-
tify current functioning as well as improvement or deteri-
oration over time. Patients are scored according to their
highest level of functioning across 8 domains with a sum-
mary score ranging from 0 (low function, dependent) to 8
(high function, independent).
Autonomy Preference Index (API) The API identifies
dimensions of autonomy by measuring patients’ prefer-
ences for making medical decisions (decision-making
subscale) and their desire to be informed (information-
seeking subscale). Higher scores indicate stronger prefer-
ences in favor of decision making or information-seeking.
Krantz Health Opinion Survey (KHOS) The KHOS
measures preferences regarding information about health-
care (information-seeking subscale) and active involvement
in healthcare (behavioral-involvement subscale). While the
API measures preference for healthcare information-
seeking behavior for decisions not necessarily already
made, the KHOS examines manifest information-seeking
and behavioral involvement. Higher scores indicate that
the patient is proactive in seeking healthcare information
and professional medical assistance.
Outcome measures
Primary outcome measures were kidney disease progres-
sion, use of KRT and subjective health-related quality of
life. Kidney disease progression was measured continu-
ously according to decrease in mean eGFR and categor-
ically per the Kidney Disease Outcomes Quality Initiative
staging system [37] using the Modification of Diet in Renal
Disease formula [38]. Use of KRT was obtained by
consented linkage to the Australia and New Zealand Dialy-
sis and Transplant Registry (ANZDATA). Health-related
quality of life was assessed using both a psychometric
health status measure (KDQOL-SF 1.3) and a utility-based
measure (EQ-5D) [39]. Health status measures discrimin-
ate levels of functioning between groups and detect
changes in function over time while utility-based measures
are utilized in cost-effectiveness analyses and to guide deci-
sions regarding resource allocation. The EuroQol Group’s
EQ-5D is commonly used to calculate quality adjusted life
years (QALYs) [40] and has been used extensively to assess
utility-based quality of life in CKD patients [41]. The EQ-
5D has five dimensions (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression). In the currentanalysis responses to the EQ-5D 3-level version were di-
chotomized as ‘no problem’ versus ‘some/severe problems’.
Statistical analysis
Data are presented descriptively as mean (standard devi-
ation) or median (range) for continuous variables, and
frequency (percentage) for categorical variables. Between-
group differences were compared with Student t test or
the chi-square test, where appropriate. Associations be-
tween psychosocial and clinical variables with health-
related quality of life were calculated using Spearman’s
correlation coefficient. Analyses were conducted using
Stata/IC version 12.0 (Statacorp, 2011) with statistical
comparison treated as significant at α = 0.05 (two-tailed).
Results
An overview of recruitment and retention is presented
in Figure 1. Of the 105 eligible patients approached to par-
ticipate, 18% (n = 19) declined participation, 21% (n = 22)
did not respond and 13% (n = 14) were lost to follow-up.
Subsequently 48% (n = 50) of those approached provided
informed consent and 47% (n = 49) completed baseline
assessments. There were no significant differences be-
tween responders and non-responders in mean age,
gender distribution and Index of Disadvantage quartiles
(all p > 0.05).
The baseline sociodemographic, clinical and laboratory
characteristics of pilot participants are displayed in
Table 1 Baseline characteristics of pilot participants, the




Age (yr; mean ± SD) [range] 73 ± 10 [37–86]
Female gender 18 (37%)
Education > Year 12 12 (25%)
Married/living as married 34 (69%)
Retired 35 (71%)
Government pension 35 (71%)
Index of Disadvantage
Quartile 1 13 (26%)
Quartile 2 13 (26%)
Quartile 3 10 (20%)
Quartile 4 14 (28%)










Declined to answer 8 (16%)
Clinical
Depression (PHQ-9 score≥ 10) 5 (10%)
Anxiety (BAI score≥ 16) 4 (9%)
Current/former smoker 27 (55%)
≥3 medical comorbidities 29 (59%)
No. of comorbidities (mean ± SD) [range] 3.3 ± 1.9 [1.0–8.0]
Hypertension 41 (84%)
Systolic BP (mm Hg; mean ± SD) 133.3 ± 22
Diastolic BP, (mm Hg; mean ± SD) 67.8 ± 12.7
Diabetes mellitus 19 (39%)
Atherosclerotic heart disease 21 (43%)
Congestive heart failure 17 (35%)
Peripheral vascular disease 14 (29%)
Grip strength, right (kg; mean ± SD) [range] 25.9 ± 8.6 [9.0–49.0]
Grip strength, left (kg; mean ± SD) [range] 26.9 ± 8.8 [12.5–47.5]
5-metre walk (sec; mean ± SD) [range] 8.0 ± 4.4 [5.0–28.0]
BMI (kg/m2; mean ± SD) [range] 30.1 ± 6.8 [21.9–53.5]
BMI < 25 kg/m2 8 (16%)
BMI 25–29.9 kg/m2 23 (47%)
Table 1 Baseline characteristics of pilot participants, the
Tasmanian Chronic Kidney Disease study (frequency (%)
unless otherwise indicated) (Continued)
BMI≥ 30 kg/m2 15 (31%)
Missing 3 (6%)
Laboratory
Hemoglobin (g/L; mean ± SD) [range] 121.5 ± 15.0 [94.0–163.0]
Serum creatinine (μmol/L; mean ± SD)
[range]
241.1 ± 61.9 [144.0–396.0]
eGFR (mL/min/1.73 m2; mean ± SD) [range] 22.2 ± 4.9 [15.0–30.0]
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male with a mean age at enrolment of 72.6 ± 10.2 years
(range 37–86 years). The majority had low educational
attainment, were married or living as married and were re-
ceiving a Government pension. Around 70% of participants
reported a household income of less than AUS$31,200 per
year. Only three participants were current smokers, while
around half (n = 24) were former smokers and over 75%
were overweight or obese. Around 60% of participants had
at least three current medical comorbidities and 39% had
at least four comorbidities. The majority of participants
were hypertensive and around 40% had diabetes mellitus.
Mean depression (PHQ-9) score was 4.4 ± 5.8 with five
participants (10%) meeting the recommended threshold
(score ≥ 10) for a clinical diagnosis of major depression.
Mean anxiety (BAI) score was 7.8 ± 7.8 with 9.3% of par-
ticipants reporting at least moderate levels of anxiety
(score ≥ 16). Mean social support (MSPSS) score was
5.8 ± 1.1 (range 2.6–7.0).
Baseline scores for the health-related quality of life
measures (KDQOL-SF 1.3 and EQ-5D) are shown in
Table 2. Mean values for the kidney disease targeted-
scales ranged from 33.7 (work status, SD = 31.3) to 87.4
(social support, SD = 21.1) on the range of total possible
(0–100) scores. Mean values for the SF-36 scales ranged
from 42.7 (role limitations–physical, SD = 41.9) to 79.6
(social function, SD = 25.9). The highest percentage of
problems reported by participants using the EQ-SD was
in the dimension pain/discomfort (61%) followed by mo-
bility (51%), usual activities (49%) and anxiety/depression
(27%).
Associations between psychosocial and biomedical
variables, and health-related quality of life subscales
(KDQOL-SF) are displayed in Table 3. Consistent in-
verse associations were observed between depression
severity (PHQ-9) and anxiety (BAI) with all of the SF-36
subscales and the majority of kidney disease-targeted
subscales. Significant positive correlations were also ob-
served between perceived social support (MSPSS) and
the cognitive function and emotional well-being subscales.
There were no significant associations between eGFR,
hemoglobin, creatinine, and health-related quality of life.
Table 2 Baseline descriptive statistics for health-related
quality of life measures (KDQOL-SF 1.3 and EQ-5D), the
Tasmanian Chronic Kidney Disease study
Variable
Kidney disease-targeted scales (mean ± SD) [range]^
Burden of kidney disease 71.9 ± 27.0 [6.3–100.0]
Quality of social interaction 80.3 ± 19.2 [26.7–100.0]
Cognitive function 84.1 ± 21.3 [0.0–100.0]
Symptoms/problems 76.1 ± 15.7 [31.8–100.0]
Effects of kidney disease 86.3 ± 16.4 [14.3–100.0]
Sexual function 65.9 ± 37.1 [0.0–100.0]
Sleep 63.2 ± 20.0 [5.0–95.0]
Social support 87.4 ± 21.1 [0.0–100.0]
Work status 33.7 ± 31.3 [0.0–100.0]
Overall health rating 64.5 ± 19.6 [20.0–100.0]
SF-36 scales
Physical Functioning 52.1 ± 29.6 [0.0–100.0]
Role limitations-physical 42.7 ± 41.9 [0.0–100.0]
Pain 66.1 ± 31.2 [0.0–100.0]
General health 43.8 ± 21.2 [0.0–85.0]
Emotional well-being 76.6 ± 20.3 [8.0–100.0]
Role limitations-emotional 63.2 ± 42.0 [0.0–100.0]
Social function 79.6 ± 25.9 [0.0–100.0]
Energy/fatigue 47.7 ± 24.5 [5.0–90.0]
SF-36 PCS 37.7 ± 10.1 [17.5–55.1]
SF-36 MCS 50.7 ± 9.4 [19.1–64.1]






^No participants were receiving dialysis at time of enrolment so ‘Staff
encouragement’ and ‘Patient satisfaction’ scales were not completed.
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90.0 ± 9.2 with scores ranging from 65 to 100. Seven par-
ticipants (15%) scored below the recommended cut-
point for lower global cognitive functioning (score < 80).
One participant had a score at the test ceiling and
no participants had scores at the test floor. Mean score
on the KDQOL-SF cognitive function subscale was
84.1 ± 21.3 with a median score of 93.3 (range 0 to 100).
Eighteen (37%) participants had scores at the test ceiling
with only one participant scoring at the test floor.
Decision making preferences indicated that the major-
ity of participants (63%, n = 30) prefer to delegate deci-
sions to healthcare professionals (API decision-making
subscale, mean score 16.6 ± 4.3) and just under half of
participants (46%, n = 22) prefer information/educationto be provided (API information-seeking subscale, 33.5 ±
3.3). Conversely, around half (49%, n = 23) reported ac-
tively seeking information (KHOS information subscale,
10.7 ± 2.1) with 40% of participants (n = 18) preferentially
seeking professional help (KHOS behavioral-involvement
subscale, 10.6 ± 1.6).
Mean ADL score was 5.6 ± 1.0 and mean IADL score
was 7.2 ± 1.3, both indicating reasonably high function-
ing. Mean KPS score was 77.6 ± 14.2 with a range of 40
to 90 also indicating reasonable functional status. Eight
participants (17.4%) were assigned a score < 70 indicat-
ing that these participants require some level of assist-
ance to carry out daily activities.
At 10-month follow-up in April 2012, one participant
had died while eight participants (16%) had progressed
to KRT and nine participants (18%) had progressed to
stage 5 CKD without KRT. The remainder of partici-
pants remained stable with stage 3 or 4 CKD. For partic-
ipants not receiving KRT at 10-month follow-up mean
serum creatinine was 288 ± 143 μmol/L with mean eGFR
20 ± 9 mls/min/1.73 m2.
Discussion
The Tasmanian Chronic Kidney Disease Study is a
prospective cohort study of community-dwelling non-
dialyzed adults with severe CKD. The study will contrib-
ute to the emerging international literature investigating
associations between psychosocial factors and kidney
disease and, to our knowledge, will be the first study to
examine the influence of these factors in adults with
CKD prior to dialysis or transplantation. The current
analysis describes the clinical, sociodemographic, psy-
chosocial and health-related quality of life characteristics
of pilot participants at baseline and their clinical pro-
gression at 10-month follow-up. Strengths include the
use of a community-based cohort and comprehensive
assessment of a range of psychosocial and biomedical
variables.
Considerable psychological morbidity was observed in
pilot participants with 10% meeting the threshold for a
diagnosis of major depression and 9% reporting at least
moderate levels of clinical anxiety. While numbers are
small, this is substantially higher than the 12-month preva-
lence of affective and anxiety disorders (4.6% and 5.2% re-
spectively) observed in Australians aged 65 to 85 years [42].
Consistent with previous research, less severe depression
was associated with higher subjective health-related quality
of life [43]. Lower levels of anxiety were also associated with
higher quality of life suggesting that anxiety symptoms may
be associated with quality of life independent to those of
depression. Anxiety and depression are distinct clinical
entities that have differing causes, pathophysiological pro-
cesses, and treatments [44]. Distinguishing between their
individual and combined effects will be important to
Table 3 Spearman correlations between the KDQOL-SF subscales and psychosocial and biomedical variables, the
Tasmanian Chronic Kidney Disease study
KDQOL-SF PHQ-9 BAI MSPSS Age Hemoglobin Creatinine eGFR CMI CF ADL KPS
Kidney disease-targeted scales
Burden of kidney disease −0.33a −0.33a −0.05 0.29a 0.03 −0.13 0.15 0.02 0.34a 0.08 −0.03
Quality of social interaction −0.56c −0.60c 0.45b 0.23 0.05 0.17 −0.12 −0.14 0.58c 0.37b 0.12
Cognitive function −0.51c −0.55c 0.47b 0.05 −0.16 0.03 −0.06 −0.20 1.00 0.36a 0.21
Symptoms/problems −0.61c −0.61c 0.11 0.15 −0.05 −0.07 0.11 −0.16 0.45b 0.21 0.18
Effects of kidney disease −0.50c −0.41b 0.13 −0.004 −0.22 −0.09 −0.02 −0.31a 0.43c 0.23 0.17
Sexual function −0.12 −0.06 −0.08 0.19 −0.18 0.23 −0.26 −0.26 −0.41 0.51 0.28
Sleep −0.67c −0.61c 0.27 0.28 0.00 −0.02 0.09 −0.36a 0.50b 0.30a 0.16
Social support −0.34a −0.25 0.54c 0.20 −0.18 −0.11 0.01 −0.36a 0.49c 0.42b 0.25
Work status −0.12 −0.06 0.17 −0.32a 0.04 0.15 −0.21 −0.14 0.09 0.13 0.23
Overall health rating −0.54c −0.44b 0.24 0.03 −0.22 0.01 −0.14 −0.46b 0.36a 0.29a 0.30a
SF-36 scales
Physical functioning −0.46b −0.52c 0.09 −0.16 0.15 0.05 −0.02 −0.38a 0.23 0.33a 0.10b
Role limitations-physical −0.45b −0.42b −0.06 −0.14 0.00 0.05 −0.03 −0.25 0.31a 0.26 0.23
Pain −0.37b −0.60c 0.12 0.08 0.14 0.05 0.01 −0.30a 0.29a 0.20 0.29
General health −0.72c −0.63c 0.13 0.19 0.08 0.04 −0.001 −0.48c 0.30a 0.16 0.27
Emotional well-being −0.50c −0.64c 0.41b 0.14 0.11 0.24 −0.21 −0.27 0.59b 0.32a 0.15
Role limitations - emotional −0.35a −0.37a −0.11 0.11 0.24 −0.06 0.20 0.14 0.06 −0.03 0.09
Social function −0.67c −0.62c 0.18 0.06 0.17 0.09 −0.10 −0.25 0.57b 0.28 0.25
Energy/fatigue −0.65c −0.68c 0.22 −0.06 −0.05 0.08 −0.07 −0.33a 0.40b 0.15 0.34a
SF36 physical composite score −0.48b −0.61c 0.15 0.08 −0.04 0.15 −0.12 −0.29 0.26 0.18 0.14
SF36 mental composite score −0.61c −0.58c 0.26 0.23 0.05 0.22 −0.11 −0.12 0.47b 0.30 0.21
ap < 0.05; bp < 0.01; cp < 0.001.
ADL, Activities of Daily Living; BAI, Beck Anxiety Inventory; CF, cognitive function subscale; CMI, Charlson comorbidity index; eGFR, estimated Glomerular Filtration
Rate; KPS, Karnofsky Performance Scale index; MSPSS, Multidimensional Scale of Perceived Social Support; PHQ-9, Patient Health Questionnaire.
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states are associated with kidney function. While per-
ceived social support (MSPSS) was comparable to popu-
lation norms [45], participants rated the quality of their
social interactions (KDQOL-SF) similarly to patients on
dialysis [29].
Substantial loss of physical well-being was also ob-
served in pilot participants with self-reported physical
functioning, general health and energy/fatigue (KDQOL-
SF) being comparable to patients on dialysis [29]. Simi-
larly, all SF-36 subscale scores, except for the emotional
well-being and the mental component summary scores,
were lower than the age and sex standardized mean
scores in the Australian population [46]. Further, over
60% of participants reported experiencing pain/discom-
fort and around 50% endorsed problems with mobility
and usual activities, further highlighting the considerable
physical symptom burden experienced by current partic-
ipants. As previously observed, there were no significant
associations between renal function parameters and
health-related quality of life [47]. A possible explanation
is that while the disease burden in current participants issubstantial they may deny the impact of their illness as a
coping mechanism.
There are several limitations of the current investiga-
tion that should be considered. As this study was designed
as a pilot to assess the feasibility of a larger cohort study a
formal power calculation was not performed. Results
should therefore be treated as preliminary and interpreted
with caution. In addition, due to the cross-sectional de-
sign, the direction of causality cannot be inferred. Further,
depressive and anxiety symptoms were ascertained via
self-report rather than standardized clinical interviews
which may underestimate the prevalence of these disor-
ders [18,48]. However all self-report measures used in the
current study have been validated in renal populations
and are brief and easy to administer and interpret. Finally,
although non-participants did not differ from participants
in terms of age, gender and socio-economic status, the po-
tential for non-response bias remains.
While the participation rate in the current study ap-
pears low, it is comparable to previous pilot studies in-
volving adults with chronic disease [49] and consistent
with evidence that those with poorer health status, lower
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http://www.biomedcentral.com/1471-2369/14/83levels of functioning and higher levels of psychological
distress are less likely to participate in population-based
research [50]. Our aim is to recruit 700 participants for
the state-wide prospective cohort study. This represents
30% of the target population [16] which is well below
the current response rate of 47%. Despite this, efforts to
increase participation and limit attrition will be import-
ant in ensuring adequate statistical power to examine as-
sociations between the key variables of interest. Future
strategies involve recruiting face-to-face via treating
physicians and assessing participants during usual care
thereby increasing response rates and reducing partici-
pant burden.
Australia will spend over AUS$11 billion on dialysis
and kidney transplantation in the next 10 years [51].
According to Australian registry data, for every new case
that receives dialysis another patient with ESKD dies
without having received it [52]. Further, for those who
do commence dialysis, around 37% will die via with-
drawal from treatment [53]. For these patients, medical
management may involve a shift from efforts to prolong
life to a more supportive/palliative care model focusing
on care, quality of life and symptom control. As a pa-
tient proceeds from the community to hospital treat-
ment, possible dialysis, then death, there are critical
opportunities to improve health and quality of life by
identifying and then modifying psychological and social
health determinants.
Conclusions
This paper describes the study design, baseline charac-
teristics and initial follow-up of pilot participants in the
Tasmanian Chronic Kidney Disease study. Current re-
sults indicate that ongoing recruitment and prospective
assessment of this cohort is feasible and has the poten-
tial to evaluate the relative impact of both biomedical
and psychosocial factors on rate of disease progression,
use of KRT, and salient personal and economic out-
comes. Findings from this study have the potential to
provide an evidence base for revising healthcare decision
making and treatment pathways in order to optimize the
care of patients with CKD.
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